Actuate Therapeutics (NASDAQ:ACTU) Given New $20.00 Price Target at HC Wainwright

Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) had its price target hoisted by investment analysts at HC Wainwright to $20.00 in a research note issued on Tuesday, Stock Target Advisor reports. The firm presently has a "buy" rating on the stock. HC Wainwright's price objective would indicate a potential upside of 119.54% from the stock's current price.

Separately, Craig Hallum started coverage on shares of Actuate Therapeutics in a report on Tuesday, April 22nd. They set a "buy" rating and a $21.00 price target on the stock.

Actuate Therapeutics Price Performance

Shares of ACTU stock traded down $0.64 during mid-day trading on Tuesday, reaching $9.11. The stock had a trading volume of 63,307 shares, compared to its average volume of 49,889. The stock's 50-day moving average price is $8.98 and its two-hundred day moving average price is $8.43. Actuate Therapeutics has a 52-week low of $5.51 and a 52-week high of $11.99.

Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) last released its quarterly earnings results on Thursday, May 15th. The company reported ($0.32) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.06).

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. BIOS Capital Management LP bought a new stake in Actuate Therapeutics in the 4th quarter worth approximately $78,753,000. Voss Capital LP grew its holdings in shares of Actuate Therapeutics by 157.7% in the first quarter. Voss Capital LP now owns 142,381 shares of the company's stock worth $964,000 after acquiring an additional 87,135 shares during the period. Sigma Planning Corp increased its position in Actuate Therapeutics by 47.3% during the first quarter. Sigma Planning Corp now owns 23,675 shares of the company's stock valued at $160,000 after acquiring an additional 7,600 shares during the last quarter. Goldman Sachs Group Inc. lifted its holdings in Actuate Therapeutics by 98.7% in the first quarter. Goldman Sachs Group Inc. now owns 22,358 shares of the company's stock valued at $151,000 after acquiring an additional 11,105 shares during the period. Finally, Mercer Global Advisors Inc. ADV purchased a new position in Actuate Therapeutics in the fourth quarter worth about $130,000.

Actuate Therapeutics Company Profile

Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.